PLSE Pulse Biosciences, Inc.
USHealthcareAs of 2026-07-09 16:00
Why PLSE matters now
Pulse Biosciences, Inc. (PLSE) is a US stock in Healthcare. The latest InvestLog snapshot shows $27.24 with -3.09% on the session and $1.89B in market capitalization; recent performance reads 1-month +2.61% and YTD +86.45%.
The latest financial table shown here is Q1 2026, with revenue of $401.0K, net income of $-18.6M, and EPS of $-0.26. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.1%.
The latest indexable market news headline is "Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $30.00; recent insider activity includes Sainz Maria filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
26.18
P/S
2359.21
EV/EBITDA
-23.09
DCF Value
$1.06
FCF Yield
-3.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-91.1%
Operating Margin
-10392.1%
Net Margin
-9929.0%
ROE
-86.7%
ROA
-91.4%
ROIC
-106.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $401.0K | $-18.6M | $-0.26 |
| Q4 2025 | $264.0K | $-17.4M | $-0.26 |
| FY 2025 | $350.0K | $-72.8M | $-1.08 |
| Q3 2025 | $86.0K | $-19.4M | $-0.29 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$30.67
Target (Median)
$30.00
Target Range
$30.00 - $32.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
1.66
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.